Esperion Therapeutics INC (ESPR) Shareholder Pentwater Capital Management LP Increased Its Stake by $5.99 Million as Shares Rose

During 2018 Q2 the big money sentiment decreased to 0.95. That’s change of 0.55, from 2018Q1’s 1.5. 43 investors sold all, 35 reduced holdings as ESPR ratio fall. 56 increased positions while 18 funds took positions. Funds hold 26.84 million shares thus 9.29% more from 2018Q1’s 24.56 million shares. Royal Bank Of Canada owns 13,235 shs. 17,403 were accumulated by Manufacturers Life Insur The. State Street has invested 0.01% of its capital in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Nomura Holdings has 250,000 shs. Fincl Bank Of Nova Scotia owns 340,000 shs. Millennium Mngmt Limited Company accumulated 86,817 shs. Bb Biotech Ag accumulated 3.18 million shs. J Goldman & LP has invested 0.19% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Balyasny Asset Mngmt Limited Liability Company holds 41,224 shs. National Bank & Trust Of Montreal Can accumulated 738 shs. Amundi Pioneer Asset Mngmt Incorporated accumulated 320,815 shs. Schwab Charles Investment Mngmt reported 111,389 shs stake. Price T Rowe Assoc Inc Md accumulated 302,903 shs or 0% of the stock. Northern Corp stated it has 591,726 shs. Creative Planning invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Pentwater Capital Management Lp’s stake in Esperion Therapeutics Inc (ESPR) is rose by 6.64% based on its latest 2018Q2 regulatory filing with the SEC. By buying 153,500 shares Pentwater Capital Management Lp made the stock popped up with 15.64%. The hedge fund is holding 2.46 million shares, compared to the 2.31 million from the previous quarter. And the reported value of the health care company is $96.56M for the 2018Q2. $1.46B is the MC of Esperion Therapeutics Inc. ESPR is touching $54.49 during the last trading session, after decreased 6.79%.Esperion Therapeutics, Inc. is downtrending after having declined 8.71% since November 10, 2017. ESPR has 933,255 volume or 33.46% up from normal. The stock underperformed the S&P500 by 24.33%.

According to a filing Pentwater Capital Management Lp decreased its stake in Aetna Inc (Put) by 105,500 shares to 1.30M shares, valued at $239.38M in 2018Q2. The fund manages about $5.28 billion and $13.68 billion US Long portfolio. Pentwater Capital Management Lp has cut its stake in Vmware Inc (Call) and also reduced its holding in Vmware Inc (NYSE:VMW) by 521,501 shares in the quarter, for a total of 405,000 shares.

For more Esperion Therapeutics, Inc. (NASDAQ:ESPR) news published recently go to:,,, or The titles are as follows: “Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid” published on October 28, 2018, “Three sell-siders bullish on Kodiak Sciences in premarket analyst action” on October 29, 2018, “74 Biggest Movers From Friday” with a publish date: November 05, 2018, “Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial …” and the last “NASDAQ: ESPR Long Term Investor Notice: Investigation of Potential Wrongdoing at Esperion Therapeutics, Inc.” with publication date: October 22, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Total analysts of 3 have positions in Esperion Therapeutics (NASDAQ:ESPR) as follows: 2 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 67%. Since July 11, 2018 according to StockzIntelligence Inc Esperion Therapeutics has 3 analyst reports. On Friday, August 17 the stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given by Citigroup. On Wednesday, July 11 the rating was downgraded by Northland Capital to “Market Perform”.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.